ArticleFrontiers in oncology2025
Synchronous double primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma in a single patient with chronic hepatitis B: two case reports and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Managing dual primary liver metastases from breast and colorectal cancers.Clinical journal of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Simultaneous occurrence of primary hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) is rare. We report two cases of synchronous double primary HCC and ICC (sdpHCC-ICC), both associated with chronic hepatitis B. Case 1 involves a 63-year-old man whose liver lesions were incidentally found during routine screening. Preoperative imaging revealed lesions in the S4 and S5 liver segments, with postoperative confirmation of sdpHCC-ICC. He received hepatic arterial infusion chemotherapy (HAIC) and transcatheter arterial chemoembolization (TACE) combined with gemcitabine and oral S-1 over 26 months, with no recurrence observed. Case 2 describes a 48-year-old woman presenting with right upper abdominal pain. Preoperative imaging identified a lesion at the S6/7 and S8 junction, later confirmed as sdpHCC-ICC. Postoperative TACE was performed at 1.5 and 3 months, and lenvatinib was introduced at 3.5 months. She remained recurrence-free at the 21-month follow-up. While the precise pathogenesis of sdpHCC-ICC remains unclear, chronic HBV infection plays a pivotal role. Surgical resection remains the primary treatment, though prognosis is generally poor due to the ICC component.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.